Posts tagged “Intersouth”
Vascular Pharmaceuticals a startup focusing on development of treatments for complications from diabetes, has closed on $3 million in new financing.
Vascular Pharmaceuticals a startup focusing on development of treatments for complications from diabetes, has closed on $9 million in new financing.
Existing investors in Advanced Animal Diagnostics have poured another $15 million into the Durham-based company, according to an SEC filing. AAD raised $6 million in 2013 for product launches and $11 million in 2011.
A spate of Triangle life science IPOs raised more total money than those in Boston and New York in 2013, and more followed early this year. Has this open IPO window affected biotech and life science fundraising in the Triangle? Will the window remain open? One area VC suggests we may look back on 2010-2015 as a watershed time for the regional industry.
The Durham-based life sciences firm lands additional financing and a new investor as it looks to bring its cancer immunotherapy to market. Intersouth Partners and Aurora Funds are among Argos investors.
Garheng Kong, a former partner at venture capital firm Intersouth Partners in Durham, is the newest member of the board at lab testing giant LabCorp.
With the Council for Entrepreneurial Development's annual Tech Venture conference this week and Southeast BIO's own conference coming up in less than two months, Suzanne Cantando has to hit the ground running in her new job as executive director for the life science organization.
Long before some VC firms generated buzz by hiring people to promote their firms and portfolios, Intersouth Partners brought on board Suzanne Cantando to handle media relations for itself and its investments. After a decade, Cantando has left to lead Southeast BIO, and the dean of N.C.'s VCs wishes her well. WRALTechWire subscribers get the inside story.
Suzanne Cantando, the director of communications for venture capital firm Intersouth Partners in Durham, is taking over as leader of Southeast BIO, a trade organization focused on advancing the life science industry across the southeast.
The Durham-based life sciences firm lands investors from Russia and Korea as it looks to bring its cancer immunotherapy to market. Intersouth Partners and Aurora Funds also participate in the round.
Venture capital firm Intersouth Partners is moving its offices to a renovated historic fire station. Learn more about the move.
New Bull City, Day Eight: In 1988, Durham had just four total life science companies. Now the city has 92 firms and counting. Read how the life sciences took root in the "City of Medicine" as WRALTechWire's report about the rebirth of Durham continues.
The New Bull City: A former tobacco building now houses several life science related firms, and space once used to process tobacco now offers research space. The history of the Venable center reflects Durham,s transition from a tobacco town to a tech hub.
New Bull City: Durham's rise as a technology and life sciences hub owes something to the city's emergence as a food town. A Durham venture capitalist explains.
HexaTech, a venture capital backed company, wins federal funding to develop a new kind of chip for the nation's power grid.
6fusion, which is backed by Intersouth partners, has raised $2 million in a mix of debt and options financing. The company hopes to raise $2 million more.
The company also strikes a deal to sell the firm after a future clinical trial to Janssen Biotech. Intersouth Partners, MPM lead the first round of financing for Vascular, which is focused on development of treatments for diabetes complications.
The venture capital backed startup, which has been funded locally by Intersouth Partners and NCIDEA, is commercializing technology developed at NC State.